Purpose: To describe characteristics of pure small cell carcinoma of prostate (SCCP) and assess the prognostic factors. Patients and Methods: We summarized data of pure SCCP from published studies and ours and made Kaplan-Meier analysis and Cox regression to evaluate prognosis factors. Results: A total of 2,213 patients with prostate cancer was identified, of which eight (0.36%) patients were pure SCCP. The mean age at diagnosis was 61 years old. And there were 2 patients diagnosed at 34 and 50 years old respectively. Symptoms of these patients were similar to patients with prostate adenocarcinoma. Serum prostate specific antigen of 7 patients was at normal level. Five patients received chemotherapy, average overall survival (OS) was 9.75 months; 3 only received conservative treatment, average OS was 4 months. By univariate and multivariate Cox analysis, chemotherapy is an independent predictor of survival. Kaplan-Meier analysis demonstrated that chemotherapy was associated with longer OS. Conclusion: Clinical characteristics, examination and treatment strategy of pure SCCP are very different from prostate adenocarcinoma. According to the data from published studies and from our studies, the average survival of patients receiving chemotherapy is longer than those who received other treatment modalities.

Keywords:
Small cell carcinoma, Chemotherapy, Prostate, Diagnosis , Prognosis
1.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.
2.
Wenk RE, Bhagavan BS, Levy R, et al: Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 1977; 40: 773–778.
3.
Yao JL, Madeb R, Bourne P, et al: Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006; 30: 705–712.
4.
Helpap B, Kollermann J, Oehler U: Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int 1999; 62: 133–138.
5.
Petraki C, Vaslamatzis M, Petraki K, et al: Prostate cancer with small-cell morphology: an immunophenotypic subdivision. Scand J Urol Nephrol 2005; 39: 455–463.
6.
Albisinni S, De Nunzio C, Tubaro A: Pure small cell carcinoma of the prostate: a rare tumor. Indian J Urol 2012; 28: 89–91.
7.
Capizzello A, Peponi E, Simou N, et al: Pure small cell carcinoma of the prostate: a case report and literature review. Case Rep Oncol 2011; 4: 88–95.
8.
Kraft Rovere R, Silva de Lima A, Casemiro KP: A case of small-cell prostate cancer with a metastasis to the scalp. Jpn J Clin Oncol 2013; 43: 1156.
9.
Sasaki M, Kobayashi T, Ono K, et al: Small cell carcinoma of the prostate: a case report. Int J Urol 1997; 4: 321–323.
10.
Benchekroun A, Nouini Y, Zannoud M, et al: Small cell carcinoma of the prostate: a case report. Ann Urol (Paris) 2002; 36: 314–317.
11.
Whitaker DA Jr, Miller DH, Jagadesh N, et al: Small cell carcinoma of the prostate in an elderly patient: a case report and review of the literature. Rare Tumors 2016; 8: 6657.
12.
Yahyazadeh SH, Abadpour B, Molanaei S, et al: Complete chemotherapeutic regression of a non-metastatic case of primary pure small cell carcinoma of the prostate. Curr Urol 2012; 6: 43–45.
13.
Kaplan M, Atakan IH, Bilgi S, et al: Case report: subcutaneous metastasis from small cell carcinoma of the prostate. Int Urol Nephrol 2007; 39: 157–160.
14.
Ketata S, Ketata H, Fakhfakh H, et al: Pure primary neuroendocrine tumor of the prostate: a rare entity. Clin Genitourin Cancer 2006; 5: 82–84.
15.
Ishizu K, Tsushimi M, Shimajiri S, et al: Small cell carcinoma of the prostate successfully treated with combined chemotherapy and radiotherapy: a case report. Hinyokika Kiyo 2002; 48: 97–100.
16.
Guanqun Li, Chunqing Feng, Chengmei Zhou, et al: An Unusual etiology of urinary retention – small cell prostate carcinoma. Urol Case Rep 2016; 7: 53–64.
17.
Kim KH, Park SU, Jang JY, et al: A case of robot-assisted laparoscopic radical prostatectomy in primary small cell prostate cancer. Korean J Urol 2010; 51: 882–884.
18.
Siegel RL1, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.
19.
Cohen A, Richards KA, Patel S, et al: Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol 2015; 33: 70.e1–e7.
20.
Wang J, Wang FW: Impact of age on clinical presentation, treatment, and cancer-specific survival of patients with small-cell carcinoma of the prostate. Clin Interv Aging 2013; 8: 871–877.
21.
Nadal R, Schweizer M, Kryvenko ON, et al: Small cell carcinoma of the prostate. Nat Rev Urol 2014; 11: 213–219.
22.
Palmgren JS, Karavadia SS, Wakefield MR: Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007; 34: 22–29.
23.
Weprin S, Yonover P: Small cell carcinoma of the prostate: a case report and brief review of the literature. Urol Case Rep 2017; 13: 61–62.
24.
Aggarwal R, Zhang T, Small EJ, et al: Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw 2014; 12: 719–726.
25.
Ishizu K, Tsushimi M, Shimajiri S, et al: Small cell carcinoma of the prostate successfully treated with combined chemotherapy and radiotherapy: a case report. Hinyokika Kiyo 2002; 48: 97–100.
26.
Mackey JR, Au HJ, Hugh J, et al: Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol 1998; 159: 1624–1629.
27.
Aparicio AM, Harzstark AL, Corn PG, et al: Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19: 3621–3630.
28.
Sandhu SS, Denton A, Jarmulowicz M, et al: Pure small cell carcinoma of the prostate. Clin Oncol (R Coll Radiol) 1997; 9: 412–414.
29.
Capizzello A, Peponi E, Simou N, et al: Pure small cell carcinoma of the prostate: a case report and literature review. Case Rep Oncol 2011; 4: 88–95.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.